These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

937 related articles for article (PubMed ID: 34817199)

  • 1. Nucleoside-Modified mRNA Vaccines Protect IFNAR
    Appelberg S; John L; Pardi N; Végvári Á; Bereczky S; Ahlén G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sällberg M; Neogi U; Weissman D; Mirazimi A
    J Virol; 2022 Feb; 96(3):e0156821. PubMed ID: 34817199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
    Hinkula J; Devignot S; Åkerström S; Karlberg H; Wattrang E; Bereczky S; Mousavi-Jazi M; Risinger C; Lindegren G; Vernersson C; Paweska J; van Vuren PJ; Blixt O; Brun A; Weber F; Mirazimi A
    J Virol; 2017 May; 91(10):. PubMed ID: 28250124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models.
    Garrison AR; Shoemaker CJ; Golden JW; Fitzpatrick CJ; Suschak JJ; Richards MJ; Badger CV; Six CM; Martin JD; Hannaman D; Zivcec M; Bergeron E; Koehler JW; Schmaljohn CS
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005908. PubMed ID: 28922426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFNα/β/γR-/- Mice Models.
    Aligholipour Farzani T; Földes K; Hanifehnezhad A; Yener Ilce B; Bilge Dagalp S; Amirzadeh Khiabani N; Ergünay K; Alkan F; Karaoglu T; Bodur H; Ozkul A
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30857305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model.
    Pavel STI; Yetiskin H; Kalkan A; Ozdarendeli A
    PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008834. PubMed ID: 33226988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.
    Dowall SD; Buttigieg KR; Findlay-Wilson SJ; Rayner E; Pearson G; Miloszewska A; Graham VA; Carroll MW; Hewson R
    Hum Vaccin Immunother; 2016; 12(2):519-27. PubMed ID: 26309231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Delivery Effect of CD24 on the Immunogenicity and Lethal Challenge Protection of a DNA Vector Expressing Nucleocapsid Protein of Crimean Congo Hemorrhagic Fever Virus.
    Aligholipour Farzani T; Hanifehnezhad A; Földes K; Ergünay K; Yilmaz E; Hashim Mohamed Ali H; Ozkul A
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30658445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mRNA Vaccine for Crimean-Congo Hemorrhagic Fever Virus Expressing Non-Fusion GnGc Using NSm Linker Elicits Unexpected Immune Responses in Mice.
    Chen T; Ding Z; Li X; Li Y; Lan J; Wong G
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge.
    Leventhal SS; Meade-White K; Rao D; Haddock E; Leung J; Scott D; Archer J; Randall S; Erasmus JH; Feldmann H; Hawman DW
    EBioMedicine; 2022 Aug; 82():104188. PubMed ID: 35907368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and evaluation of DNA vaccine encoding Crimean Congo hemorrhagic fever virus nucleocapsid protein, glycoprotein N-terminal and C-terminal fused with LAMP1.
    Hu YL; Zhang LQ; Liu XQ; Ye W; Zhao YX; Zhang L; Qiang ZX; Zhang LX; Lei YF; Jiang DB; Cheng LF; Zhang FL
    Front Cell Infect Microbiol; 2023; 13():1121163. PubMed ID: 37026060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Novel Multi-Epitope Vaccine Against Crimean-Congo Hemorrhagic Fever Virus: An Integrated Reverse Vaccinology, Vaccine Informatics and Biophysics Approach.
    Tahir Ul Qamar M; Ismail S; Ahmad S; Mirza MU; Abbasi SW; Ashfaq UA; Chen LL
    Front Immunol; 2021; 12():669812. PubMed ID: 34220816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice.
    Kortekaas J; Vloet RP; McAuley AJ; Shen X; Bosch BJ; de Vries L; Moormann RJ; Bente DA
    Vector Borne Zoonotic Dis; 2015 Dec; 15(12):759-64. PubMed ID: 26684523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent human plasma candidate reference materials protect against Crimean-Congo haemorrhagic fever virus (CCHFV) challenge in an A129 mouse model.
    Kempster S; Hassall M; Graham V; Kennedy E; Findlay-Wilson S; Salguero FJ; Bagci B; Elaldi N; Oz M; Tasseten T; Charlton FW; Barr JN; Fontana J; Duru C; Ezeajughi E; Matejtschuk P; Arnold U; Adedeji Y; Mirazimi A; Hewson R; Dowall S; Almond N
    Virus Res; 2024 Aug; 346():199409. PubMed ID: 38815869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral replicon particles protect IFNAR
    Spengler JR; Welch SR; Scholte FEM; Rodriguez SE; Harmon JR; Coleman-McCray JD; Nichol ST; Montgomery JM; Bergeron É; Spiropoulou CF
    Antiviral Res; 2021 Jul; 191():105090. PubMed ID: 34044061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever.
    Rodriguez SE; Cross RW; Fenton KA; Bente DA; Mire CE; Geisbert TW
    Sci Rep; 2019 May; 9(1):7755. PubMed ID: 31123310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crimean-Congo Hemorrhagic Fever Mouse Model Recapitulating Human Convalescence.
    Hawman DW; Meade-White K; Haddock E; Habib R; Scott D; Thomas T; Rosenke R; Feldmann H
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31292241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus.
    Wang Q; Cao R; Li L; Liu J; Yang J; Li W; Yan L; Wang Y; Yan Y; Li J; Deng F; Zhou Y; Wang M; Zhong W; Hu Z
    Antiviral Res; 2022 Mar; 199():105273. PubMed ID: 35257725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model.
    Saunders JE; Gilbride C; Dowall S; Morris S; Ulaszewska M; Spencer AJ; Rayner E; Graham VA; Kennedy E; Thomas K; Hewson R; Gilbert SC; Belij-Rammerstorfer S; Lambe T
    EBioMedicine; 2023 Apr; 90():104523. PubMed ID: 36933409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge.
    Zivcec M; Safronetz D; Scott DP; Robertson S; Feldmann H
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006628. PubMed ID: 30011277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus.
    Zivcec M; Guerrero LIW; Albariño CG; Bergeron É; Nichol ST; Spiropoulou CF
    Antiviral Res; 2017 Oct; 146():112-120. PubMed ID: 28842265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.